Familial Adenomatous Polyposis Coli - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 39 pages report, published by Global Markets Direct

Keywords : Familial Adenomatous Polyposis Coli Therapeutic Products under Development, Key Players in Familial Adenomatous Polyposis Coli Therapeutics, Familial Adenomatous Polyposis Coli Pipeline Overview, Familial Adenomatous Polyposis Coli Pipeline, Familial Adenomatous Polyposis Coli Pipeline Assessment

Report ThumbnailSeptember-2013
Familial Adenomatous Polyposis Coli - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Familial Adenomatous Polyposis Coli - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Familial Adenomatous Polyposis Coli, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Familial Adenomatous Polyposis Coli. Familial Adenomatous Polyposis Coli - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Familial Adenomatous Polyposis Coli.
- A review of the Familial Adenomatous Polyposis Coli products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Familial Adenomatous Polyposis Coli pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Familial Adenomatous Polyposis Coli.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Familial Adenomatous Polyposis Coli pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Familial Adenomatous Polyposis Coli, H2 2013 7
  • Products under Development for Familial Adenomatous Polyposis Coli - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Late Stage Products, H2 2013 10
  • Pre-Clinical Stage Products, H2 2013 11
  • Assessment by Monotherapy Products, H2 2013 17
  • Assessment by Combination Products, H2 2013 18
  • Assessment by Route of Administration, H2 2013 19
  • Assessment by Stage and Route of Administration, H2 2013 20
  • Assessment by Molecule Type, H2 2013 21
  • Assessment by Stage and Molecule Type, H2 2013 22
  • List of Tables
  • Number of Products Under Development for Familial Adenomatous Polyposis Coli, H2 2013 7
  • Products under Development for Familial Adenomatous Polyposis Coli - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Comparative Analysis by Late Stage Development, H2 2013 10
  • Comparative Analysis by Pre-Clinical Stage Development, H2 2013 11
  • Products under Development by Companies, H2 2013 12
  • Products under Investigation by Universities/Institutes, H2 2013 13
  • Astellas Pharma Inc., H2 2013 14
  • MDRNA, Inc., H2 2013 15
  • S.L.A. Pharma AG, H2 2013 16
  • Assessment by Monotherapy Products, H2 2013 17
  • Assessment by Combination Products, H2 2013 18
  • Assessment by Stage and Route of Administration, H2 2013 20
  • Assessment by Stage and Molecule Type, H2 2013 22
  • Familial Adenomatous Polyposis Coli Therapeutics - Drug Profile Updates 29
  • Familial Adenomatous Polyposis Coli Therapeutics - Dormant Products 31
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Familial Adenomatous Polyposis Coli Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Familial Adenomatous Polyposis Coli 7
  • Familial Adenomatous Polyposis Coli Therapeutics under Development by Companies 9
  • Late Stage Products 10
  • Comparative Analysis 10
  • Pre-Clinical Stage Products 11
  • Comparative Analysis 11
  • Familial Adenomatous Polyposis Coli Therapeutics - Products under Development by Companies 12
  • Familial Adenomatous Polyposis Coli Therapeutics - Products under Investigation by Universities/Institutes 13
  • Companies Involved in Familial Adenomatous Polyposis Coli Therapeutics Development 14
  • Astellas Pharma Inc. 14
  • MDRNA, Inc. 15
  • S.L.A. Pharma AG 16
  • Familial Adenomatous Polyposis Coli - Therapeutics Assessment 17
  • Assessment by Monotherapy Products 17
  • Assessment by Combination Products 18
  • Assessment by Route of Administration 19
  • Assessment by Molecule Type 21
  • Drug Profiles 23
  • exisulind - Drug Profile 23
  • Product Description 23
  • Mechanism of Action 23
  • R&D Progress 23
  • CEQ-501 - Drug Profile 25
  • Product Description 25
  • Mechanism of Action 25
  • R&D Progress 25
  • icosapent - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • eflornithine hydrochloride + sulindac - Drug Profile 27
  • Product Description 27
  • Mechanism of Action 27
  • R&D Progress 27
  • Familial Adenomatous Polyposis Coli Therapeutics - Drug Profile Updates 29
  • Familial Adenomatous Polyposis Coli Therapeutics - Dormant Products 31
  • Familial Adenomatous Polyposis Coli - Product Development Milestones 32
  • Featured News & Press Releases 32
  • May 20, 2011: European Medicines Agency Concludes On Use Of Celecoxib In Familial Adenomatous Polyposis 32
  • Apr 12, 2011: Pfizer Announces Encouraging Data From Open-Label Extension Study Of Tafamidis 32
  • Apr 30, 2007: Pfizer Wins Celebrex Patent Decision in Canadian Court, Launch of Generic Product by Novopharm Prohibited until 2014 33
  • Mar 20, 2007: Pfizer Wins Celebrex Patent Challenge by Generic 33
  • Feb 23, 2007: Celebrex Label Extended for New Use in Europe. 34
  • Aug 01, 2005: US FDA Approves New Use for Pfizer's Celebrex For Patients with Ankylosing Spondylitis. 34
  • Dec 21, 2004: Pfizer Says New NIH Study Results are Consistent with Large Body of Evidence Supporting Cardiovascular Safety of Celebrex 34
  • Dec 17, 2004: Pfizer Statement on New Information Regarding Cardiovascular Safety of Celebrex 35
  • Oct 19, 2004: Pfizer to Sponsor Major New Celebrex Clinical Trial 36
  • May 22, 2003: Pfizer Inc.'s (PFE) Celebrex (Celecoxib Capsules) Linked To Significantly Lower Incidence Of Medication-Induced Damage To The Small Bowel 37
  • Appendix 38
  • Methodology 38
  • Coverage 38
  • Secondary Research 38
  • Primary Research 38
  • Expert Panel Validation 38
  • Contact Us 39
  • Disclaimer 39

Please select a license type

Share

Related Products

Global Markets DirectFamilial Adenomatous Polyposis Coli - Pipeline Review, H2 2013Product ThumbnailFamilial Adenomatous Polyposis Coli - Pipeline Review, H2 2013, Industry ReportProduct #: 113342
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved